Xenon Pharmaceuticals (NASDAQ:XENE) Insider Andrea Difabio Sells 2,607 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Andrea Difabio sold 2,607 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the transaction, the insider directly owned 4,893 shares of the company’s stock, valued at $294,118.23. The trade was a 34.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Xenon Pharmaceuticals Trading Down 2.6%

Xenon Pharmaceuticals stock traded down $1.57 during trading on Wednesday, hitting $59.04. The company had a trading volume of 5,546,191 shares, compared to its average volume of 1,583,794. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of -13.54 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $63.95. The company’s 50 day simple moving average is $43.23 and its 200-day simple moving average is $41.69.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the business posted ($0.84) earnings per share. As a group, analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently bought and sold shares of XENE. Kestra Advisory Services LLC purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $33,000. Blue Trust Inc. increased its stake in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the period. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals during the third quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Analyst Upgrades and Downgrades

A number of brokerages recently commented on XENE. Deutsche Bank Aktiengesellschaft raised their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday. Bank of America reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday. Stifel Nicolaus set a $66.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday. Finally, Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $71.94.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.